INgezim® COVID RBD-DR
CE-marked double recognition enzyme-linked immunosorbent assay for detecting antibodies specific to S (RBD) of SARS-CoV-2 in human serum samples.
INgezim® COVID RBD-DR is designed to semi-quantitatively determine total SARS-CoV-2 virus S (RBD)-protein-specific antibodies in human serum samples, to assist in the diagnosis of COVID-19 disease; as a complementary tool to the direct detection of the pathogen. In addition, serology can help to gather epidemiological information on the disease prevalence. This highly sensitive test is particularly recommended for the early detection of SARS-CoV-2 specific antibodies as it favours the detection of IgM.
|Test principle||Double recognition enzyme-linked immunosorbent assay|